Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial

Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    - The page now reflects a shift from “Active, not recruiting” and various past dates to a more definitive status with newer dates and the label “Actual.” The timeline references have been updated to 2025 dates, and the update labeling changes to include “Last Update Posted (Estimated)” followed by a 2025-10- date.
    Difference
    2%
    Check dated 2025-10-20T14:22:46.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    - Added a government-operating-status notice and a path to updates, plus a version bump to v3.2.0. - Removed the previous version tag v3.1.0.
    Difference
    4%
    Check dated 2025-10-06T06:57:46.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    Updated page version to v3.1.0 and removed the Plasma cell myeloma resource; overall, a minor content change with no new core information added.
    Difference
    0.5%
    Check dated 2025-09-29T03:36:05.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Update to v3.0.2 (replacing v3.0.1). Removed the 'Back to Top' link, a minor UI change.
    Difference
    0.2%
    Check dated 2025-09-14T21:39:22.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content or other important factors.
    Difference
    0.2%
    Check dated 2025-09-07T18:06:03.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of new medical topics such as plasma cell myeloma and hemic and lymphatic diseases. Notably, the drug daratumumab has been added, indicating a focus on specific treatments.
    Difference
    2%
    Check dated 2025-08-31T12:20:50.000Z thumbnail image

Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.